Ritlecitinib lower dose
Sponsors
Pfizer
Conditions
Severe Alopecia Areata
Phase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
RecruitingNCT07029828
Start: 2025-09-10End: 2030-06-26Target: 140Updated: 2026-04-28
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Active, not recruitingNCT07029711
Start: 2025-07-31End: 2027-01-06Updated: 2026-08-26